- Source type
- Clinical resource
- Access type
- Publisher
- Publisher
- Riley Children's Health
- Date
- 2026-06-14
- Added
- 2026-07-05
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
82
Professional clinical guidance
- Publisher type
- Professional guidance
- Bias profile
- Moderate
This source is strongest for safety and consumer context and weaker for mechanism and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 63/100
- Context Source
- Clinical outcomes
- 78/100
- Strong Support
- Mechanism
- 63/100
- Context Source
- Safety
- 86/100
- Strong Support
- Consumer context
- 82/100
- Strong Support
- Trial discovery
- 63/100
- Context Source
Best used for
- Clinical context
- Practice guidance
Weak for
- Replacing primary evidence
Used in Viral Vitalism
Teen Became First Pediatric Patient Saved by Deceased-Donor Stem Cells
Roles: Primary source
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
FDA: Casgevy expanded to young children with sickle cell disease
Primary regulatory source for the July 2026 Casgevy age-expansion brief.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 1 connection
FDA: Tregzi approval press announcement
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
Indiana Public Media: Bloomington resident receives successful deceased-donor stem cell transplant
Local reporting confirmation for Noah Britt deceased-donor stem cell transplant milestone.
- Trust score
- 60
- Publisher
- Indiana Public Media
- Access
- Publisher
- Usage
- 1 connection
Children's National: first-of-its-kind cell therapy trial in aggressive brain tumors
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Children's National
- Access
- Publisher
- Usage
- 1 connection
Orca Bio: Phase 3 Precision-T data background
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Orca Bio
- Access
- Publisher
- Usage
- 1 connection